All In Biotech

Drug Trial Radar · NCT01613417

Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain

Phase IV, Double-blind, Multi-center, Randomized, Crossover Study to Compare 0.1 mmol/kg of Prohance® With 0.1 mmol/kg of Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH)

Last checked: Nov 19, 2026Latest source record: Jul 1, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 229 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

229

Actual

Start

Aug 2012

Primary completion

Apr 2014

Study completion Apr 2014

Sponsor

Lead sponsor
Bracco Diagnostics, IncIndustry
Sponsor type
Industry
First posted
Jun 7, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims at a direct comparison between ProHance (0.1 mmol/kg) and a validated comparator Gadovist/Gadavist (0.1 mmol/kg) in a crossover intra-individual design in subjects with brain tumors to confirm the identical overall technical and diagnostic performance of the two MR contrast agents.

Conditions

  • Brain Disease

Interventions

  • gadoteridolDrug

    ProHance 0.1 mmol/kg

  • gadobutrolDrug

    Gadovist/Gadavist 0.1 mmol/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Global Diagnostic Preference Between the Two ExamsTime frame: Comparison of image sets obtained within 2 to 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Holy Name Medical Center

    Teaneck, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.